scientific studies plus the 10-working day monotherapy clinical study with single injections. The antiretroviral exercise of Lenacapavir is unaffected by any mutation conferring resistance to more mature antiretrovirals. Lenacapavir is slowly but surely produced from the web site of injection and this demands an initial protection by its oral formu